Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.74 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | DPYD | Q12882 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uracil SCHEMBL27874550 | 0.86 | CRBN (0.90) | CRBNMMP2TP53DPYDTYMP | |
| Uracil SCHEMBL5089507 | 0.86 | — | — | |
| Uracil SCHEMBL8235 | 0.86 | — | — | |
| Uracil SCHEMBL3798527 | 0.86 | CRBN (1.00) | CRBNMMP2TP53DPYDTYMP | |
| Uracil SCHEMBL11607890 | 0.86 | — | — | |
| Uracil SCHEMBL28867999 | 0.84 | CRBN (0.85) | CRBNMMP2TP53DPYDTYMP | |
| Uracil SCHEMBL28426792 | 0.84 | CRBN (0.85) | CRBNMMP2TP53DPYDTYMP | |
| Uracil SCHEMBL16116311 | 0.84 | — | — | |
| Uracil SCHEMBL4664232 | 0.84 | CRBN (0.94) | CRBNMMP2TP53DPYDTYMP | |
| Uracil SCHEMBL21385227 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512162-B2 | Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites and oligonucleotides | ASED, LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9493773-B2 | Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides | ASED, LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-9365607-B1 | Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides | ASED, LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150252071-A1 | Synthesis of Deuterated Ribo Nucleosides, N-Protected Phosphoramidites and Oligonucleotides | ASED, LLC | 2015-09-10 | — | — | US | disclosed |
| EP-2882769-A2 | SYNTHESIS OF DEUTERATED RIBO NUCLEOSIDES, N-PROTECTED PHOSPHORAMIDITES, AND OLIGONUCLEOTIDES | Ased, LLC (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2882768-A2 | SYNTHESIS OF DEUTERATED RIBO NUCLEOSIDES, N-PROTECTED PHOSPHORAMIDITES, AND OLIGONUCLEOTIDES | Ased, LLC (US) | 2015-06-17 | — | — | EP | disclosed |
| US-9045521-B2 | Synthesis of deuterated ribo nucleosides N-protected phosphoramidites, and oligonucleotides | ASED, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150119565-A1 | SYNTHESIS OF DEUTERATED RIBO NUCLEOSIDES, N-PROTECTED PHOSPHORAMIDITES, AND OLIGONUCLEOTIDES | ASED, LLC | 2015-04-30 | — | — | US | disclosed |
| US-8859754-B2 | Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides | ASED, LLC (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2014022563-A2 | SYNTHESIS OF DEUTERATED RIBO NUCLEOSIDES, N-PROTECTED PHOSPHORAMIDITES, AND OLIGONUCLEOTIDES | ASED, LLC (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20140039178-A1 | Synthesis of deuterated ribo nucleosides N-protected phosphoramidites, and oligonucleotides | ASED, LLC | 2014-02-06 | — | — | US | disclosed |
| WO-2014022566-A2 | SYNTHESIS OF DEUTERATED RIBO NUCLEOSIDES, N-PROTECTED PHOSPHORAMIDITES, AND OLIGONUCLEOTIDES | ASED, LLC (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20140039175-A1 | Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides | ASED, LLC | 2014-02-06 | — | — | US | disclosed |
| US-20110040082-A1 | Modifications of antimetabolite gemcitabine for incorporation in CpG oligonucleotides | SRIVASTAVA SURESH C | 2011-02-17 | — | — | US | disclosed |
| US-7846436-B2 | Oligonucleotides and related compounds | CHEMGENES CORPORATION (US) | 2010-12-07 | — | — | US | disclosed |
| US-20050159375-A1 | Novel oligonucleotides and related compounds | CHEMGENES CORPORATION | 2005-07-21 | — | — | US | disclosed |
| US-6015886-A | ANTISENSE AGENTS WITH MODIFICATIONS INCLUDING P-ALKOXY AND 2'-O-METHYL GROUPS; NUCLEASE RESISTANT, ABILITY TO ACTIVATE BACTERIAL RIBONUCLEASE H, FORM STABLE DUPLEXES WITH RNA, AND HAVE STRONG HYDROPHOBICITY FOR EFFICIENT CELLULAR UPTAKE | CHEMGENES CORPORATION (US) | 2000-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159375-A1 | Novel oligonucleotides and related compounds | DCLRE1B, TYMP, DUT | CRBN 2667/4885MMP2 4177/4885TP53 95/4885 |
| US-20140039178-A1 | Synthesis of deuterated ribo nucleosides N-protected phosphoramidites, and oligonucleotides | NSUN3, RNGTT, DUT | CRBN 1964/4885MMP2 4276/4885TP53 1913/4885 |
| US-20110040082-A1 | Modifications of antimetabolite gemcitabine for incorporation in CpG oligonucleotides | MTAP, TYMP, DUT | CRBN 4589/4885MMP2 2844/4885TP53 166/4885 |
| US-20140039175-A1 | Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides | NSUN3, RNGTT, DUT | CRBN 1939/4885MMP2 4355/4885TP53 1755/4885 |
| US-20150252071-A1 | Synthesis of Deuterated Ribo Nucleosides, N-Protected Phosphoramidites and Oligonucleotides | NSUN3, DUT, RNGTT | CRBN 1854/4885MMP2 4277/4885TP53 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.